KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (OTC BB: PVCT), a development-stage oncology and dermatology biopharmaceutical company, announced today that it has received approximately $1.1 million from the early conversion of some of its outstanding warrants. The Company now has approximately $5 million cash on hand to fund operations.
